000152084 001__ 152084
000152084 005__ 20250326144155.0
000152084 0247_ $$2doi$$a10.3390/antibiotics10040381
000152084 0248_ $$2sideral$$a126913
000152084 037__ $$aART-2021-126913
000152084 041__ $$aeng
000152084 100__ $$0(orcid)0000-0002-1924-7201$$aMuñoz-Muñoz, L.$$uUniversidad de Zaragoza
000152084 245__ $$aRepurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria
000152084 260__ $$c2021
000152084 5060_ $$aAccess copy available to the general public$$fUnrestricted
000152084 5203_ $$aInfections caused by nontuberculous mycobacteria (NTM) are increasing worldwide, resulting in a new global health concern. NTM treatment is complex and requires combinations of several drugs for lengthy periods. In spite of this, NTM disease is often associated with poor treatment outcomes. The anti-parasitic family of macrocyclic lactones (ML) (divided in two subfamilies: avermectins and milbemycins) was previously described as having activity against mycobacteria, including Mycobacterium tuberculosis, Mycobacterium ulcerans, and Mycobacterium marinum, among others. Here, we aimed to characterize the in vitro anti-mycobacterial activity of ML against a wide range of NTM species, including Mycobacteroides abscessus. For this, Minimum Inhibitory Concentration (MIC) values of eight ML were determined against 80 strains belonging to nine different NTM species. Macrocyclic lactones showed variable ranges of anti-mycobacterial activity that were compound and species-dependent. Milbemycin oxime was the most active compound, displaying broad-spectrum activity with MIC lower than 8 mg/L. Time kill assays confirmed MIC data and showed bactericidal and sterilizing activity of some compounds. Macrocyclic lactones are available in many formulations and have been extensively used in veterinary and human medicine with suitable pharmacokinetics and safety properties. This information could be exploited to explore repurposing of anti-helminthics for NTM therapy.
000152084 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragón$$9info:eu-repo/grantAgreement/ES/DGA/LMP132-18
000152084 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000152084 590__ $$a5.222$$b2021
000152084 591__ $$aPHARMACOLOGY & PHARMACY$$b68 / 279 = 0.244$$c2021$$dQ1$$eT1
000152084 591__ $$aINFECTIOUS DISEASES$$b39 / 95 = 0.411$$c2021$$dQ2$$eT2
000152084 592__ $$a0.785$$b2021
000152084 593__ $$aBiochemistry$$c2021$$dQ1
000152084 593__ $$aMicrobiology$$c2021$$dQ1
000152084 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2021$$dQ1
000152084 593__ $$aPharmacology (medical)$$c2021$$dQ1
000152084 593__ $$aMicrobiology (medical)$$c2021$$dQ1
000152084 594__ $$a3.9$$b2021
000152084 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000152084 700__ $$aShoen, C.
000152084 700__ $$aSweet, G.
000152084 700__ $$0(orcid)0000-0003-4198-6622$$aVitoria, A.
000152084 700__ $$aBull, T.J.
000152084 700__ $$aCynamon, M.
000152084 700__ $$aThompson, C.J.
000152084 700__ $$0(orcid)0000-0002-8480-0325$$aRamón-García, S.
000152084 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000152084 773__ $$g10, 4 (2021), 381 [9 pp.]$$pAntibiotics$$tAntibiotics$$x2079-6382
000152084 8564_ $$s668120$$uhttps://zaguan.unizar.es/record/152084/files/texto_completo.pdf$$yVersión publicada
000152084 8564_ $$s2665066$$uhttps://zaguan.unizar.es/record/152084/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000152084 909CO $$ooai:zaguan.unizar.es:152084$$particulos$$pdriver
000152084 951__ $$a2025-03-26-13:54:47
000152084 980__ $$aARTICLE